HOME >> BIOLOGY >> NEWS
Adult stem cells to repair hearts damaged by severe coronary artery disease investigated

CHICAGO - Rush University Medical Center is one of the first medical centers in the country, and currently the only site in Illinois, participating in a novel clinical trial to determine if a subjects own stem cells can treat a form of severe coronary artery disease.

The Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia (ACT34-CMI) Trial is the first human, Phase II adult stem cell therapy study in the U.S. designed to investigate the efficacy, tolerability, and safety of blood-derived selected CD34+ stem cells to improve symptoms and clinical outcomes in subjects with chronic myocardial ischemia (CMI), a severe form of coronary artery disease.

"What were hoping is that these stem cells will be able to stimulate the growth of new blood vessels to bring more blood and oxygen to the heart muscle, so that these patients will have a better quality of life and less chest pain," said Dr. Gary Schaer, director of the Rush Cardiac Catheterization Lab and study investigator.

Myocardial ischemia is a serious heart condition that involves narrowing of coronary arteries and results in limited blood flow to the heart. The disease affects hundreds of thousands of new people each year. A person who suffers from chronic myocardial ischemia continues to experience insufficient flow of oxygen-rich blood to the heart despite optimum medical intervention.

The study is a randomized, double-blind, placebo-controlled study that involves adult subjects with severe coronary artery disease who are currently on the maximum medical therapy and who are not suitable candidates for conventional procedures to improve blood flow to the heart such as angioplasty, stents, or coronary artery bypass surgery.

Rush is one of 15 to 20 research sites nationwide participating in the study, which is sponsored by the Cellular Therapies business unit of Baxter Healthcare Corporation. Baxter technology is used to select the subjects own CD34+ stem
'"/>

Contact: Mary Ann Schultz
Mary_Ann_Schultz@rush.edu
312-942-7816
Rush University Medical Center
1-Feb-2007


Page: 1 2 3

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Adult stem cells from human cord umbilical cord blood successfully engineered to make insulin
3. Adult stem/progenitor cells repair of damaged brain, pancreas, kidney cells newly understood
4. Adult neurogenesis newly adult-born neurons are functionally similar to mature neurons
5. Adults who go to bed lonely get stress hormone boost next morning
6. Adult stem cells are touchy-feely, need environmental clues
7. Adult stem cell research at UB targets damaged hearts
8. 4th International Conference on Teenage and Young Adult Cancer Medicine
9. Adult human neural stem cell therapy successful in treating spinal cord injury
10. Adult stem cells from adipose tissue could save lives
11. Adults can be retrained to learn second languages more easily, says UCL scientist

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... SOUTHFIELD, Mich. (PRWEB) , ... August 11, 2020 ... ... Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with ... discovery and development. Both Roche and J&J have annual Research and Development ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval ... CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be assigned a ... The company’s solutions are the first Wharton’s jelly allograft product to be recognized as ...
(Date:7/22/2020)... ... July 21, 2020 , ... ... in technology and compliance, announces a new solution to manage regulated workloads on ... layer of their technology stack complies with FDA and global regulations. USDM's new ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... life sciences, biotechnology, and diagnostics companies, has announced the placement of Julianne ... will be responsible for leading all financial operations and implementing key business strategies ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... available for free its new white paper – Simulated Transport Methodologies. Regulatory ... today’s biologics licensing application (BLA). In response, Modality Solutions shares an explanation ...
(Date:7/31/2020)... ... 29, 2020 , ... R3 Stem Cell International is now offering patients the ... stem cells total, patients may choose which extremities they would like treated. , Several ... Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab ...
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
Breaking Biology Technology:
Cached News: